GVSAP and Biocytogen Boost India's Biopharma Innovation with Expanded Collaboration

The GV Safety Assessment Platform partners with Biocytogen to enhance India's biotech research capabilities. The expanded collaboration offers pharmacology services and cell line access, fostering efficient drug discovery. This initiative underscores India's evolving biopharma landscape and elevates the nation's preclinical research standards.

The GV Safety Assessment Platform (GVSAP), a key player in preclinical R&D, is expanding its strategic partnership with Biocytogen, a global biotech firm. This move aims to significantly enhance the biopharma ecosystem in India by improving access to advanced biomedical research tools.

The strengthened alliance, building on an existing collaboration, will now encompass pharmaceutical services and licensing for gene-edited cell lines. This expansion supports various stages of research, from target validation to pharmacological evaluation, streamlining workflows for Indian researchers.

Kalyan Korisapati, CEO of GVSAP, highlights the importance of this partnership in facilitating precision-driven drug discovery in India. Yuelei Shen, CEO of Biocytogen, emphasizes the growing demand for cutting-edge biotech solutions in India's rapidly evolving biopharma sector.

(With inputs from agencies.)